Form 4: Esperion Therapeutics Executive Eric Warren Reports Sale of Shares to Cover Tax Obligations

Esperion Therapeutics' Chief Commercial Officer, Eric Warren, sold 239 shares of common stock on February 19, 2025, to satisfy tax obligations related to vested restricted stock units.

Summary

• On February 19, 2025, Eric Warren, Chief Commercial Officer of Esperion Therapeutics, Inc., sold 239 shares of common stock.
• The sale was executed at a price of $1.868 per share.
• The transaction was conducted to cover tax obligations arising from the vesting of restricted stock units.
• Following the transaction, Warren directly owns 159,759 shares of Esperion Therapeutics.
• The transaction was reported on a Form 4 filing with the SEC.
• Warren has a power of attorney agreement in place with Sheldon L. Koenig and Richard B. Bartram, allowing them to execute SEC filings on his behalf.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an executive's stock sale for tax purposes. It doesn't convey any particularly positive or negative sentiment about the company's performance or future prospects.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning or tax obligations. The sale itself doesn't necessarily indicate a negative outlook for the company, but it's important to monitor insider transactions for any patterns or significant changes in ownership.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but the transaction is small and related to tax obligations, so the impact is likely to be minimal.

Key Dates